May 8th Is World Ovarian Cancer Day – Mercy Launches New Study Investigating HIPEC For Ovarian Cancer
Ovarian cancer is sometimes called the “silent killer,” as by the time it is discovered, it is often in Stage III or Stage IV. Hence, statistics which show that just 45% of women with ovarian cancer are likely to survive for five years (versus up to 89% of women with breast cancer).
May 8th is World Ovarian Cancer Day, a great time for women to improve their knowledge when it comes to the diagnosis and treatment of this disease. For example, many women mistakenly believe the cervical smear test (Pap test) will detect ovarian cancer.
Symptoms are often confused with other less serious conditions, such as gastrointestinal issues. Ovarian cancer symptoms may include persistent bloating, difficulty eating and feeling full quickly, needing to pass urine more frequently, abdominal and pelvic pain.
The current standard of treatment for patients with advanced ovarian cancer is surgery followed by systemic chemotherapy. Mercy, a known Peritoneal Surface Malignancy Center, has achieved significant success treating abdominal cancers like appendix cancer and peritoneal cancer through the use of surgery and HIPEC—Hyperthermic (or heated) IntraPeritoneal Chemotherapy.
“We hypothesize that patients newly diagnosed with advanced stage epithelial ovarian, primary peritoneal, or fallopian tube cancers can be successfully treated with surgery, HIPEC and systemic chemotherapy,” said Dr. Armando Sardi, Director, The Institute for Cancer Care at Mercy and a noted expert in HIPEC.
According to Dr. Sardi, the hope is that by using this approach, patients will have less recurrence of the disease, improved patient survival without compromising a long-term quality of life.
“Our single center study is a randomized phase II trial with the aims of assessing postoperative recovery related to CRS and HIPEC, demonstrating improvement in overall survival, identifying risk factors, determining prognostic and predictive factors affecting treatment, and evaluating health-related quality of life,” said Mercy gynecologic oncologist Dr. Teresa Diaz-Montes, who is working with Dr. Sardi on the study which is now in the recruitment phase.
Founded in 1874 in downtown Baltimore by the Sisters of Mercy, Mercy Medical Center is a 183-licensed bed acute care university-affiliated teaching hospital. Mercy has been recognized as a top Maryland hospital by U.S. News & World Report; a Top 100 hospital for Women’s Health & Orthopedics by Healthgrades; is currently A-rated for Hospital Safety (Leapfrog Group), and is recognized by the American Nurses Credentialing Center as a Magnet Hospital. Mercy Medical Center is part of Mercy Health Services (MHS), the parent of Mercy’s primary care and specialty care physician enterprise, known as Mercy Personal Physicians, which employs more than 200 providers with locations in Baltimore, Lutherville, Overlea, Glen Burnie, Columbia and Reisterstown. For more information about Mercy, visit www.mdmercy.com, MDMercyMedia on Facebook, Twitter, or call 1-800-MD-Mercy.